Health
Generics makers appeal to fix tax on treatment
Medicines for Europe to appeal the decision on its challenge to Urban Wastewater Treatment Directive. Medicines for Europe, which represents the generic and biosimilar industry, is fighting tooth and nail to address what it considers disproportionate costs that will be imposed on the pharma sector by the current extended producer responsibility (EPR) scheme embedded in the Urban Wastewater Treatment Directive (UWWTD).
Yesterday, Medicines for Europe announced its decision to challenge the Court of First Instance's decision that it lacked legal standing to challenge the UWWTD. The technical decision meant that the Court did not address the substance of their arguments.
The Directive, which was adopted with little fanfare in 2024, has attracted growing controversy. Pharmaceuticals are one of the sectors - along with cosmetics - which have been identified in the legislation for an extended producer responsibility levy. ‘Extended producer responsibility’ will...

Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
FIFA4 days agoFIFA faces mounting challenges ahead of 2026 World Cup ticket rush
-
Aviation/airlines3 days agoCommission and Eurocontrol launch platform to improve monitoring of the non-CO₂ climate impacts of aviation
-
EU law4 days agoEU outlines plans for 'clear' legislation
-
Maritime4 days agoEnforcing EU fisheries rules will strengthen competitiveness, resilience and food security, says Oceana
